These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20714110)

  • 1. Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment.
    Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
    Neurodegener Dis; 2011; 8(3):109-16. PubMed ID: 20714110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
    Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
    Mov Disord; 2010 Mar; 25(4):489-93. PubMed ID: 20063406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa.
    Agil A; Durán R; Barrero F; Morales B; Araúzo M; Alba F; Miranda MT; Prieto I; Ramírez M; Vives F
    J Neurol Sci; 2006 Jan; 240(1-2):31-6. PubMed ID: 16219327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.
    Müller T; Muhlack S
    Mov Disord; 2011 Feb; 26(3):543-6. PubMed ID: 21462263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbidopa/levodopa pharmacy errors in Parkinson's disease.
    Khadem NR; Nirenberg MJ
    Mov Disord; 2010 Dec; 25(16):2867-71. PubMed ID: 20818662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood markers of oxidative stress in Parkinson's disease.
    Younes-Mhenni S; Frih-Ayed M; Kerkeni A; Bost M; Chazot G
    Eur Neurol; 2007; 58(2):78-83. PubMed ID: 17565220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage.
    Prigione A; Begni B; Galbussera A; Beretta S; Brighina L; Garofalo R; Andreoni S; Piolti R; Ferrarese C
    Neurobiol Dis; 2006 Jul; 23(1):36-43. PubMed ID: 16563783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 10. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease.
    Cornetta T; Palma S; Aprile I; Padua L; Tonali P; Testa A; Cozzi R
    Cell Biol Toxicol; 2009 Aug; 25(4):321-30. PubMed ID: 18523852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease.
    Gatto EM; Carreras MC; Pargament GA; Riobo NA; Reides C; Repetto M; Fernandez Pardal MM; Llesuy S; Poderoso JJ
    Mov Disord; 1996 May; 11(3):261-7. PubMed ID: 8723142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease. From theory to practice.
    Ahlskog JE
    Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
    [No Abstract]   [Full Text] [Related]  

  • 16. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case studies in the advancement of Parkinson's disease.
    Frei K; Truong DD; Wolters E
    CNS Spectr; 2008 Dec; 13(12 Suppl 18):1-6. PubMed ID: 19179948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug therapy of Parkinson's disease].
    Zhou XD
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
    [No Abstract]   [Full Text] [Related]  

  • 20. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.